Kamlesh Khunti MD, PhD, FRCP, FRCGP, FMedSciProfessor, Primary Care Diabetes and Vascular Medicine, University of Leicester; Co-Director, Diabetes Research Centre, Leicester General Hospital, Leicester, United Kingdom
Kamlesh Khunti is Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, UK. He is Co-Director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have cardiometabolic disease or are at increased risk of developing cardiometabolic diseases. His work has influenced national and international guidelines on the screening and management of people with diabetes. Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations (ARC) East Midlands, Director of Centre for BME Health and Director of The Real World Evidence Unit. He is a NIHR Senior Investigator and Principal Investigator on several major national and international studies. He has published over 800 publications. Professor Khunti is a Fellow of the Academy of Medical Sciences and is currently an advisor to the Department of Health, Member of the International KDIGO on diabetes & CKD and Clinical Advisor for the National Institute for Health and Care Excellence (NICE) and Steering Board Member of the Primary Care Study Group of the European Association for the Study of Diabetes. He is Past Chair of the Department of Health–RCGP Committee on Classification of Diabetes and is Past Chair of the NICE Guidelines on Prevention of Diabetes. Professor Khunti is a Fellow of the Academy of Medical Sciences and an advisor to the Department of Health. He is the National NIHR ARC Theme Lead for Multimorbidity and Ethnicity and Diversity. He is also Honorary Visiting Professorial Fellow with Department of General Practice, University of Melbourne. In addition, he is Co-Director of the Diabetes MSc at Leicester University. He has won numerous awards nationally and internationally.
Professor Khunti has acted as consultant, advisory board member and speaker for Amgen, Astrazeneca, Bayer, NAPP, Lilly, Merck Sharp and Dohme, Novartis, Novo Nordisk, Roche, Berlin-Chemie AG/Menarini Group, Sanofi-Aventis, Servier, Bohringer Ingelheim, grants from Pfizer, Bohringer Ingelheim, AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Servier.